Daniel Bensen

Net worth: 7 M $ as of 2024-04-29

49 year

Health Technology

Consumer Services

Profile

Daniel Bensen is the founder and the Chief Operating Officer of Tyra Biosciences, Inc., a company founded in 2018.
He previously worked as a Principal Scientist at Trius Therapeutics, Inc. from 2007 to 2014, and as the Head-Immunology & Protein Chemistry at Cidara Therapeutics, Inc. from 2014 to 2018.
Mr. Bensen obtained his undergraduate degree from Point Loma Nazarene University and an MBA from USC Marshall School of Business.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
TYRA BIOSCIENCE, INC 0.82%	2024-03-10	431,683 ( 0.82% )	7 M $	2024-04-29

Daniel Bensen active positions

Companies	Position	Start
TYRA BIOSCIENCES, INC.	Founder	2018-08-01

All active positions of Daniel Bensen

Former positions of Daniel Bensen

Companies	Position	End
CIDARA THERAPEUTICS, INC.	Corporate Officer/Principal	2018-10-31
Trius Therapeutics, Inc. Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.	Corporate Officer/Principal	2014-01-31

See the detail of Daniel Bensen's experience

Training of Daniel Bensen

Point Loma Nazarene University	Undergraduate Degree
USC Marshall School of Business	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Daniel Bensen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
TYRA BIOSCIENCES, INC.	Health Technology
CIDARA THERAPEUTICS, INC.	Health Technology

Private companies	1
Trius Therapeutics, Inc. Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.	Health Technology